Hypera SA (HYPMY) recently announced a dividend of $0.06 per share, payable on a date yet to be confirmed, with the ex-dividend date set for October 5, 2023. As investors eagerly anticipate this ...

Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have ...

Hypera SA (HYPMY) recently announced a dividend of $0.02 per share, payable on a date yet to be confirmed, with the ex-dividend date set for 2024-03-22. As investors look forward to this upcoming ...

SAO PAULO, Oct 24 (Reuters) - The board of directors of Brazil's pharmaceutical company Hypera (HYPE3.SA), opens new tab has unanimously decided to reject rival EMS's offer to merge, it said on ...

Brazil's leading pharmaceutical company Hypera SA believes it can sustain market share gains it had this year and deliver on guidance for 2022, CEO Breno Oliveira told analysts in a conference call on ...

Brazilian pharmaceutical company Hypera has discussed a takeover offer from rival company NC Group, the owner of EMS SA, but talks are not currently active, one source with knowledge of the matter ...

Hypera SA (HYPMY) recently announced a dividend of $0.02 per share, payable on a date yet to be confirmed, with the ex-dividend date set for 2024-03-22. As investors look forward to this upcoming ...

SAO PAULO (Reuters) - Brazil's Hypera Pharma said on Monday that it has signed a contract to buy a portfolio of 18 products from Japan's Takeda Pharmaceutical Co for $825 million. Shares in Hypera ...

Brazilian pharmaceutical company Hypera said on Thursday it expects 1.7 billion reais ($331.83 million) in net income for 2022. The company also said it sees its 2022 adjusted earnings before interest ...